CORRECTION article

Front. Immunol., 11 June 2024

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1430460

Corrigendum: Late-stage MC38 tumours recapitulate features of human colorectal cancer – implications for appropriate timepoint selection in preclinical studies

  • 1. School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

  • 2. Department of Pathology, Otago Medical School, University of Otago, Dunedin, New Zealand

  • 3. Liver Injury and Cancer Program, Centenary Institute, Sydney, NSW, Australia

  • 4. Charles Perkins Centre, University of Sydney, Sydney, NSW, Australia

  • 5. Faculty of Science, University of Canterbury, Christchurch, New Zealand

In the published article, there was an error in Figure 10 (panel D) as published. The representative density plot labelled “p15E-reactive TIL” is incorrect and has been mistakenly duplicated from the plot above labelled “Total CD3+CD8+ TIL”. The existing caption for this Figure is correct as published. The corrected Figure 10 appears below:

Figure 10

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

colorectal cancer, immunotherapy, syngeneic preclinical models, MC38, immune exclusion, t cell exhaustion, tumour microenvironment

Citation

Shields NJ, Peyroux EM, Ferguson AL, Steain M, Neumann S and Young SL (2024) Corrigendum: Late-stage MC38 tumours recapitulate features of human colorectal cancer – implications for appropriate timepoint selection in preclinical studies. Front. Immunol. 15:1430460. doi: 10.3389/fimmu.2024.1430460

Received

10 May 2024

Accepted

31 May 2024

Published

11 June 2024

Volume

15 - 2024

Edited and reviewed by

Peter Brossart, University of Bonn, Germany

Updates

Copyright

*Correspondence: Nicholas J. Shields,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics